Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer 54 seconds ago, 4:02 AM PST Via GlobeNewswire
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities (DLTs) observed to date -- -- No rash observed to date --
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more